Scholarlink

<p>The gut dysbiosis is associated with the progression of Parkinson’s disease (PD). Probiotics have been demonstrated to impact disease progression via the gut-brain axis. This study aims to investigate the therapeutic potential of <i>Akkermansia Muciniphila</i> Akk11&#xa0;(Akk11) in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mouse model. Our results indicated that Akk11 administration significantly improved the MPTP-induced behavioral abnormalities, reduced the loss of dopaminergic neurons, microglia activation, reversed the production of inflammatory cytokines, and colonic damage. Mechanistic studies showed that Akk11 administration suppressed inflammatory responses by inhibiting microglial NLRP3 inflammasome activation. In summary, Akk11 alleviated MPTP-induced motor deficits and neural damage by inhibiting microglial NLRP3 inflammasome. These findings suggest that Akk11 supplementation has therapeutic potential in treating PD through the gut-brain axis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Akkermansia muciniphila Akk11 Supplementation Attenuates MPTP-Induced Neurodegeneration by Inhibiting Microglial NLRP3 Inflammasome

  • 期刊论文

  • 发表日期：

    2025年3月6日

查看全文
  • Wei Wang,
  • Shijie Shi,
  • Mingyu Su,
  • Ye Li,
  • Xiaoyu Yao,
  • Jiajun Jiang,
  • Wenxi Yao,
  • Xiaoling Qin,
  • Zhe Wang,
  • Chuanxi Tang

摘要

The gut dysbiosis is associated with the progression of Parkinson’s disease (PD). Probiotics have been demonstrated to impact disease progression via the gut-brain axis. This study aims to investigate the therapeutic potential of Akkermansia Muciniphila Akk11 (Akk11) in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mouse model. Our results indicated that Akk11 administration significantly improved the MPTP-induced behavioral abnormalities, reduced the loss of dopaminergic neurons, microglia activation, reversed the production of inflammatory cytokines, and colonic damage. Mechanistic studies showed that Akk11 administration suppressed inflammatory responses by inhibiting microglial NLRP3 inflammasome activation. In summary, Akk11 alleviated MPTP-induced motor deficits and neural damage by inhibiting microglial NLRP3 inflammasome. These findings suggest that Akk11 supplementation has therapeutic potential in treating PD through the gut-brain axis.